Menu

Menu

Menu

FastWave: The Next Generation of Intravascular Lithotripsy (IVL)

Led by proven medtech entrepreneurs, we’re developing two differentiated IVL energy systems to advance the treatment of calcific disease.

Lethal but Treatable: Coronary Artery Disease (CAD) and Peripheral Artery Disease (PAD)

Lethal but Treatable: Coronary Artery Disease (CAD) and Peripheral Artery Disease (PAD)

1 in 4 deaths in the U.S. is caused by CAD.¹

Every year, CAD causes 17.8 million deaths globally.¹

A limb is amputated every 3-5 minutes in the U.S.²

1 in 2 patients die from amputation within 1 year.³

Calcium is Highly Prevalent in CAD and PAD

Calcium is Highly Prevalent in CAD and PAD

Calcific plaque, which is prevalent in about 30% of CAD patients⁴, resists vessel expansion, making it difficult to treat with today’s interventional modalities.

Calcific plaque, which is prevalent in about 30% of CAD patients⁴, resists vessel expansion, making it difficult to treat with today’s interventional modalities.

"We continue to encounter coronary and peripheral disease complicated by severe calcium."

Dr. Amir Kaki

Interventional Cardiologist

"Calcium poses significant therapeutic challenges in treating peripheral artery disease."

Dr. Venkatesh Ramaiah

Vascular Surgeron

IVL Has Been Rapidly Adopted for Calcific Disease Treatment

The utilization of IVL for percutaneous coronary interventions is expected to grow at a 49% annual compounded rate due to its ease of use, favorable safety profile, and exceptional therapeutic efficacy.⁵

Learn More

Learn More

Learn More

FastWave is Empowering Physicians with Advanced IVL Technology

FastWave is Empowering Physicians with Advanced IVL Technology

Our focus is clear: build upon the established success of IVL technology to enable interventionalists to deliver improved treatments and better outcomes for their patients.

Our focus is clear: build upon the established success of IVL technology to enable interventionalists to deliver improved treatments and better outcomes for their patients.

First-Generation IVL

First-Generation IVL

Artero™ Peripheral IVL

Artero™
Peripheral IVL

Sola™ Coronary IVL

Sola™
Coronary IVL

Ease of Use

Ease of Use

Pulse Count Availability

Pulse Count Availability

Crossability & Deliverability

Crossability & Deliverability

Consistent & Predictable Sonic Pressure

Consistent & Predictable Sonic Pressure

Balloon Lengths

Balloon Lengths

360-degree Sonic Coverage

360-degree Sonic Coverage

Learn More

Learn More

Learn More

Learn More

In our FIH study for PAD, we successfully treated 9 limbs across 8 patients with 100% lesions crossed with a mean residual diameter stenosis of only 5.5%, or a 93% reduction from baseline, indicating an almost complete resolution of blockages.

In our FIH study for PAD, we successfully treated 9 limbs across 8 patients with 100% lesions crossed with a mean residual diameter stenosis of only 5.5%, or a 93% reduction from baseline, indicating an almost complete resolution of blockages.

Successful First-in-Human (FIH) Study

Successful First-in-Human (FIH) Study

Successful First-in-Human (FIH) Study

See More Evidence

See More Evidence

See More Evidence

In our FIH study for PAD, we successfully treated 9 limbs across 8 patients with 100% lesions crossed, with a mean residual diameter stenosis of only 5.9%. This was a 93% reduction from baseline, indicating an almost complete resolution of blockages.

Overview

Investigators

Dr. Miguel Montero-Baker, Venkatesh Ramaiah, and Antonio Muñoa

Location

San Lucas Hospital, Chiapas, Mexico

Dates

January 11-12, 2024

Results

9 successfully treated limbs across 8 patients

100% of lesions crossed, including 3 CTOs

Post-treatment mean residual diameter stenosis of 5.9%

0% AEs with no balloon ruptures

FastWave is Advancing at an
Unparalleled Pace

February 2021

FastWave established as a stand-alone Delaware C-corp.

August 2021

FastWave raises $12M Series A round of financing.

November 2022

USPTO grants FastWave its first utility patent within 6 months of filing.

April 2023

USPTO grants FastWave its second IVL utility patent.

June 2023

FastWave closes oversubscribed private financing round within a few weeks.

January 2024

FastWave completes enrollment for the first-in-human study of its peripheral IVL system.

March, April, and May 2024

USPTO grants FastWave its third, fourth, and fifth IVL utility patents.

June 2024

FastWave closes oversubscribed $19M financing round in less than a month.

December 2024

USPTO grants FastWave its sixth IVL utility patent.

January 2025

USPTO grants Fastwave its seventh IVL utility patent.

Meet Our Team

See the Rest

See the Rest

See the Rest

Curt Goreham-Voss, PhD

Principal Engineer

Curt Goreham-Voss, PhD

Principal Engineer

Curt Goreham-Voss, PhD

Principal Engineer

Scott Nelson

Co-Founder and CEO

Scott Nelson

Co-Founder and CEO

Scott Nelson

Co-Founder and CEO

Tristan Tieso

COO

Tristan Tieso

COO

Tristan Tieso

COO

Sukanya Iyer

Head of Technology

Sukanya Iyer

Head of Technology

Sukanya Iyer

Head of Technology

Julie Harrison

Systems Engineer

Julie Harrison

Systems Engineer

Julie Harrison

Systems Engineer

Lauren Fischer

Program Director

Lauren Fischer

Program Director

Lauren Fischer

Program Director

Trent Mengel

Head of Clinical

Trent Mengel

Head of Clinical

Trent Mengel

Head of Clinical

Brady Hatcher

Co-Founder and Director

Brady Hatcher

Co-Founder and Director

Brady Hatcher

Co-Founder and Director

JC Sun, PhD

Co-Founder and Director

JC Sun, PhD

Co-Founder and Director

JC Sun, PhD

Co-Founder and Director

Anindita Sengupta

Head of QA/RA

Anindita Sengupta

Head of QA/RA

Invest in the Future of IVL

We oversubscribed our last round of financing in just a few weeks, so don’t miss out on the next opportunity to invest.

Learn More

$40M+ raised from corporate venture, VC, and KOLs.

100% lesions crossed in successful first-in-human study.

Only market incumbent acquired in 2024 by J&J for $13B.

Invest in the Future of IVL

We oversubscribed our last round of financing in just a few weeks, so don’t miss out on the next opportunity to invest.

Learn More

$40M+ raised from corporate venture, VC, and KOLs.

100% lesions crossed in successful first-in-human study.

Only market incumbent acquired in 2024 by J&J for $13B.

Invest in the Future of IVL

We oversubscribed our last round of financing in just a few weeks, so don’t miss out on the next opportunity to invest.

Learn More

$40M+ raised from corporate venture, VC, and KOLs.

100% lesions crossed in successful first-in-human study.

Only market incumbent acquired in 2024 by J&J for $13B.

Follow FastWave's Journey

Next-level intravascular lithotripsy (IVL) devices for calcific artery disease.

© 2025 FastWave Medical Inc.

Home

About

Team

Peripheral

Coronary

Science

News

Invest

Contact

FastWave Medical is developing devices limited by Federal (or United States) law to investigational use. To see FastWave’s patents, click here.

¹ Source: https://pubmed.ncbi.nlm.nih.gov/32119297

² Source: https://accessprosthetics.com/15-limb-loss-statistics-may-surprise

³ Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC3329303

⁴ Source: https://recintervcardiol.org/en/review-articles/calcified-coronary-artery-disease-pathophysiology-intracoronary-imaging-assessment-and-plaque-modification-techniques#ref1

⁵ Source: https://idataresearch.com/product/intravascular-lithotripsy-global-market

Follow FastWave's Journey

Next-level intravascular lithotripsy (IVL) devices for calcific artery disease.

© 2025 FastWave Medical Inc.

Home

About

Team

Peripheral

Coronary

Science

News

Invest

Contact

FastWave Medical is developing devices limited by Federal (or United States) law to investigational use. To see FastWave’s patents, click here.

¹ Source: https://pubmed.ncbi.nlm.nih.gov/32119297

² Source: https://accessprosthetics.com/15-limb-loss-statistics-may-surprise

³ Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC3329303

⁴ Source: https://recintervcardiol.org/en/review-articles/calcified-coronary-artery-disease-pathophysiology-intracoronary-imaging-assessment-and-plaque-modification-techniques#ref1

⁵ Source: https://idataresearch.com/product/intravascular-lithotripsy-global-market

Follow FastWave's Journey

Next-level intravascular lithotripsy (IVL) devices for calcific artery disease.

© 2025 FastWave Medical Inc.

Home

About

Team

Peripheral

Coronary

Science

News

Invest

Contact

FastWave Medical is developing devices limited by Federal (or United States) law to investigational use. To see FastWave’s patents, click here.

¹ Source: https://pubmed.ncbi.nlm.nih.gov/32119297

² Source: https://accessprosthetics.com/15-limb-loss-statistics-may-surprise

³ Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC3329303

⁴ Source: https://recintervcardiol.org/en/review-articles/calcified-coronary-artery-disease-pathophysiology-intracoronary-imaging-assessment-and-plaque-modification-techniques#ref1

⁵ Source: https://idataresearch.com/product/intravascular-lithotripsy-global-market

Follow FastWave's Journey

Next-level intravascular lithotripsy (IVL) devices for calcific artery disease.

© 2025 FastWave Medical Inc.

Home

About

Team

Peripheral

Coronary

Science

News

Invest

Contact

FastWave Medical is developing devices limited by Federal (or United States) law to investigational use. To see FastWave’s patents, click here.

¹ Source: https://pubmed.ncbi.nlm.nih.gov/32119297

² Source: https://accessprosthetics.com/15-limb-loss-statistics-may-surprise

³ Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC3329303

⁴ Source: https://recintervcardiol.org/en/review-articles/calcified-coronary-artery-disease-pathophysiology-intracoronary-imaging-assessment-and-plaque-modification-techniques#ref1

⁵ Source: https://idataresearch.com/product/intravascular-lithotripsy-global-market